Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo

Keyphrases

• Placebo 100%
• Cyclooxygenase-2 Inhibitors 100%
• Prostatectomy 100%
• Celecoxib 100%
• Double-blind Randomized Study 100%
• Prostate Cancer Chemoprevention 100%
• Confidence Interval 50%
• Androgen Receptor 37%
• Apoptosis 25%
• Total Prostate-specific Antigen 25%
• Safety Concerns 25%
• Radical Prostatectomy 25%
• Prostate Tissue 25%
• Prostaglandin Receptors 25%
• Apoptosis Index 25%
• Myocardial Infarction 12%
• Twice Daily 12%
• Placebo Groups 12%
• Tumor Cells 12%
• Biological Effects 12%
• Localized Prostate Cancer 12%
• Opiates 12%
• Prostate-specific Antigen Level 12%
• Benign Tissue 12%
• Chemopreventive 12%
• Drug Safety 12%
• Cancer Tissue 12%
• Prostaglandin E2 Receptor 12%
• Benign Prostate Disease 12%
• Selective Drugs 12%
• Postoperative Opioids 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Cyclooxygenase 2 100%
• Prostate Cancer 100%
• Celecoxib 100%
• Androgen Receptor 37%
• Opiate 25%
• Prostate Specific Antigen 25%
• Prostaglandin Receptor 25%
• Heart Infarction 12%
• Neoplasm 12%
• Drug Safety 12%
• Chemopreventive Agents 12%
• Prostaglandin E Receptor 12%